Moolec Science (MLEC) Amortization of Deferred Charges (2023 - 2024)
Moolec Science (MLEC) reported Amortization of Deferred Charges of $7040.0 for Q4 2024, down 80.59% on a YoY basis from $36273.0 in Q1 2024, and down 81.82% sequentially from $38732.0 in Q3 2024.
Moolec Science (MLEC) Amortization of Deferred Charges (2023 - 2024) Analysis & Trends
Moolec Science (MLEC) has 2 years of Amortization of Deferred Charges data on file, last reported at $7040.0 in Q4 2024.
- For the quarter ending Q4 2024, Amortization of Deferred Charges fell 80.59% year-over-year to $7040.0; the trailing twelve-month figure through Dec 2024 stood at $123237.0 (changed N/A YoY), and the FY2024 full-year result was $123632.0, changed N/A from the prior year.
- Amortization of Deferred Charges retreated to $7040.0 in Q4 2024, from $38732.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $135364.0 in Q2 2024 to a low of -$57899.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Moolec Science | 5.21 Bn | 5.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 7,040.00 |
| Dec 31, 2024 | 7,040.00 |
| Sep 30, 2024 | 38,732.00 |
| Sep 30, 2024 | 38,732.00 |
| Jun 30, 2024 | 135,364.00 |
| Jun 30, 2024 | 135,364.00 |
| Mar 31, 2024 | -57,899.00 |
| Mar 31, 2024 | -57,899.00 |
| Dec 31, 2023 | 36,273.00 |
| Dec 31, 2023 | 36,273.00 |
| Sep 30, 2023 | 9,894.00 |
| Sep 30, 2023 | 9,894.00 |